To determine whether the presence of melanoma affected the frequencies of TAA-specific CD4+ T cells in patients, we analyzed MAGE-6- or EphA2-reactive CD4+ T cells in individuals with no evidence of disease (NED) vs. patients with AD. The gene discussed is EPHA2; the disease is melanoma.